ngm621
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT04014777)
Timeline
Indications
Mechanism of action
- Complement C3INHIBITOR
C3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04582318 | Phase 1/Phase 2 (Phase 2) | Nov 8, 2020 | NGM Biopharmaceuticals, Inc |
| NCT04465955 | Phase 2 | Jul 22, 2020 | NGM Biopharmaceuticals, Inc |
| NCT04014777 | Phase 1 | Jul 31, 2019 | NGM Biopharmaceuticals, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NGM Biopharmaceuticals, Inc | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1